Abstract 11858: Combination Therapy with Finerenone and Empagliflozin by Baseline Risk of Liver Fibrosis in the CONFIDENCE Trial
Abstract
Background: The liver is an important organ in cardio-kidney-metabolic (CKM) disease because of its essential roles in glucose homeostasis, cholesterol synthesis, and drug metabolism. We evaluated whether baseline liver fibrosis risk, estimated using the Fibrosis-4 (FIB-4) index, influenced treatment responses to established CKM therapies. Methods: CONFIDENCE was a double-blind, randomized, active-controlled trial evaluating combination therapy with the non-steroidal mineralocorticoid receptor antagonist finerenone and the sodium-glucose cotransporter-2 inhibitor empagliflozin in patients with chronic kidney disease (CKD) and type 2 diabetes. Adults with CKD (eGFR 30-90 mL/min/1.73 m 2 ), albuminuria (urinary albumin-to-creatinine (UACR) ratio 100-≤5000), and type 2 diabetes were randomized 1:1:1 to finerenone 10 or 20 mg/day, empagliflozin 10 mg/day, or combination therapy. The primary endpoint was relative change in log-transformed mean UACR from baseline to Day 180. FIB-4 was calculated as age х AST / (platelets х √ALT) and categorized as low risk (<1.3 if age <65 years; <2.0 if age ≥65 years), intermediate risk (1.3-2.67 if age <65 years; 2.0-2.67 if age ≥65 years), and high risk (>2.67). Linear regression with covariates and stratification factors from the original trial was used to assess treatment effect across FIB-4 categories. Results: Among 755 patients with complete data, the mean baseline FIB-4 score was 1.53 (SD 0.86); 551 (73.0%) were low risk, 145 (19.2%) intermediate risk, and 59 (7.8%) high risk. Mean FIB-4 remained essentially unchanged from baseline to Day 180 (overall mean change 0.006 [SD 0.67]), with no significant differences between the treatment groups (p=0.49). Combination therapy reduced UACR across all FIB-4 groups (low risk: combination -57.0%, vs finerenone -37.3%, vs empagliflozin -33.2%), intermediate risk: combination -48.7%, vs finerenone -35.4%, vs empagliflozin -31.7%, high risk: combination -45.1%, vs finerenone -42.9%, vs empagliflozin -49.1%) ( Figure 1A ). The beneficial effect of combination therapy vs monotherapy was generally consistent across FIB-4 categories (combination therapy vs finerenone: P for interaction = 0.49; combination therapy vs empagliflozin: P for interaction = 0.27) ( Figure 1B ). Conclusions: Approximately 1 in 4 patients with type 2 diabetes and CKD were at intermediate or high risk for liver fibrosis. Combination therapy with finerenone and empagliflozin reduced levels of albuminuria across a range of liver fibrosis risk.